# FULC catalysts: Fulcrum Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/fulc/catalysts

> Fulcrum Therapeutics, Inc. (FULC) has no upcoming catalysts in this calendar. The latest recorded is the pociredir primary completion, June 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for FULC?

Fulcrum Therapeutics, Inc. (FULC) has no upcoming catalysts in this calendar. The latest recorded is the pociredir primary completion, June 4, 2026. ClinicalTrials.gov: "NCT07401823 (Open-Label Extension Study to Pioneer Study 6058-SCD-101): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor Fulcrum Therapeutics." [Calendar and source filings](https://sec-api.dev/companies/fulc/catalysts)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT07401823 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/companies/fulc/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Fulcrum Therapeutics, Inc. |
| Ticker | FULC (Nasdaq) |
| SEC CIK | 1680581 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/fulc |

## Cash runway

Cash $116.4M as of 2026-09-30; quarterly burn $13.4M; about 26.1 months of runway at that rate (XBRL company facts, accession 0001193125-26-458453).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [Losmapimod topline data readout](https://sec-api.dev/pdufa/losmapimod) | FULC |  | completed, mixed | "For example, we invested significant time and effort into developing losmapimod for facioscapulohumeral muscular dystrophy, or FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024, and we thereafter discontinued development." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1680581/000119312526326098/fulc-20260630.htm)) |
| November 13, 2024 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/fulc-ex99_1.htm)) |
| February 25, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/fulc-ex99_1.htm)) |
| May 1, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/fulc-ex99_1.htm)) |
| July 29, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/fulc-ex99_1.htm)) |
| October 29, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/fulc-ex99_1.htm)) |
| February 24, 2026 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/fulc-ex99_1.htm)) |
| April 23, 2026 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/fulc-ex99_1.htm)) |
| June 4, 2026 | [Pociredir primary completion](https://sec-api.dev/pdufa/pociredir) | FULC | Sickle Cell Disease | withdrawn | "NCT07401823 (Open-Label Extension Study to Pioneer Study 6058-SCD-101): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor Fulcrum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07401823)) |

## Drugs

- [Losmapimod](https://sec-api.dev/pdufa/losmapimod): 
- [Pociredir](https://sec-api.dev/pdufa/pociredir): Sickle Cell Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/fulc/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FULC catalysts: Fulcrum Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/fulc/catalysts

```bibtex
@misc{secapidev_companies_fulc_catalysts_20261116,
  title        = {FULC catalysts: Fulcrum Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/fulc/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_fulc_catalysts_20261116","title":"FULC catalysts: Fulcrum Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/fulc/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
